MX2017011598A - Metodos para tratar proteinopatias. - Google Patents
Metodos para tratar proteinopatias.Info
- Publication number
- MX2017011598A MX2017011598A MX2017011598A MX2017011598A MX2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A MX 2017011598 A MX2017011598 A MX 2017011598A
- Authority
- MX
- Mexico
- Prior art keywords
- proteinopathy
- subject
- methods
- quinuclidine compound
- administering
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- -1 quinuclidine compound Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 208000034799 Tauopathies Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131071P | 2015-03-10 | 2015-03-10 | |
| PCT/US2016/021512 WO2016145046A1 (en) | 2015-03-10 | 2016-03-09 | Methods for treating proteinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011598A true MX2017011598A (es) | 2017-12-20 |
Family
ID=55587378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011598A MX2017011598A (es) | 2015-03-10 | 2016-03-09 | Metodos para tratar proteinopatias. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20180036295A1 (enExample) |
| EP (2) | EP3267983B1 (enExample) |
| JP (2) | JP6990110B2 (enExample) |
| KR (1) | KR20170123329A (enExample) |
| CN (1) | CN107872976A (enExample) |
| AU (1) | AU2016229826A1 (enExample) |
| CA (1) | CA2978883A1 (enExample) |
| EA (1) | EA201791993A1 (enExample) |
| ES (1) | ES2973101T3 (enExample) |
| HK (1) | HK1244217A1 (enExample) |
| HU (1) | HUE065628T2 (enExample) |
| IL (1) | IL254393A0 (enExample) |
| MX (1) | MX2017011598A (enExample) |
| PL (1) | PL3267983T3 (enExample) |
| PT (1) | PT3267983T (enExample) |
| TW (1) | TW201642855A (enExample) |
| WO (1) | WO2016145046A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| BR112019027029A2 (pt) * | 2017-06-19 | 2020-07-14 | Kainos Medicine, Inc. | moduladores de alfa-sinucleina |
| TWI644673B (zh) * | 2017-07-27 | 2018-12-21 | 百朗克股份有限公司 | 頭孢曲松的用途 |
| JP7633169B2 (ja) * | 2019-02-04 | 2025-02-19 | ジェンザイム・コーポレーション | グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置 |
| JP7511567B2 (ja) * | 2019-02-04 | 2024-07-05 | ジェンザイム・コーポレーション | リソソーム蓄積性疾患と関連する症状および障害を処置するための方法 |
| ES2984255T3 (es) * | 2019-11-15 | 2024-10-29 | Yuhan Corp | Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos |
| US12083115B2 (en) * | 2020-02-03 | 2024-09-10 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| JP7637121B2 (ja) * | 2020-03-17 | 2025-02-27 | 住友ファーマ株式会社 | オキサジアゾール誘導体 |
| CN115715189A (zh) * | 2020-03-23 | 2023-02-24 | 普拉西斯精密医药公司 | Kcnt1抑制剂和使用方法 |
| BR112023000798A2 (pt) * | 2020-07-24 | 2023-02-07 | Genzyme Corp | Composições farmacêuticas compreendendo venglustat |
| CA3187086A1 (en) * | 2020-07-30 | 2022-02-03 | Tanya Zaremba FISCHER | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| AU2023403087A1 (en) | 2022-12-01 | 2025-07-17 | Genzyme Corporation | Venglustat in combination with a strong or moderate inhibitor of cyp3a4 |
| WO2025262570A1 (en) | 2024-06-17 | 2025-12-26 | Genzyme Corporation | Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683A (en) | 1846-08-08 | waring and richard e | ||
| US195A (en) | 1837-05-15 | Machine fob cutting and dressing stone | ||
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| PT2685986T (pt) * | 2011-03-18 | 2020-03-05 | Genzyme Corp | Inibidor de glicosilceramida-sintase |
| CA2840224C (en) * | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
-
2016
- 2016-03-08 TW TW105107080A patent/TW201642855A/zh unknown
- 2016-03-09 WO PCT/US2016/021512 patent/WO2016145046A1/en not_active Ceased
- 2016-03-09 CA CA2978883A patent/CA2978883A1/en not_active Abandoned
- 2016-03-09 ES ES16711088T patent/ES2973101T3/es active Active
- 2016-03-09 PT PT167110881T patent/PT3267983T/pt unknown
- 2016-03-09 US US15/556,444 patent/US20180036295A1/en not_active Abandoned
- 2016-03-09 PL PL16711088.1T patent/PL3267983T3/pl unknown
- 2016-03-09 CN CN201680026839.XA patent/CN107872976A/zh active Pending
- 2016-03-09 MX MX2017011598A patent/MX2017011598A/es unknown
- 2016-03-09 EA EA201791993A patent/EA201791993A1/ru unknown
- 2016-03-09 HU HUE16711088A patent/HUE065628T2/hu unknown
- 2016-03-09 AU AU2016229826A patent/AU2016229826A1/en not_active Abandoned
- 2016-03-09 EP EP16711088.1A patent/EP3267983B1/en active Active
- 2016-03-09 HK HK18103748.9A patent/HK1244217A1/zh unknown
- 2016-03-09 JP JP2017547448A patent/JP6990110B2/ja active Active
- 2016-03-09 KR KR1020177027604A patent/KR20170123329A/ko not_active Withdrawn
- 2016-03-09 EP EP23217745.1A patent/EP4349408A3/en active Pending
-
2017
- 2017-09-10 IL IL254393A patent/IL254393A0/en unknown
-
2020
- 2020-03-02 US US16/807,102 patent/US20200197374A1/en active Pending
-
2021
- 2021-05-06 JP JP2021078459A patent/JP7374149B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL254393A0 (en) | 2017-11-30 |
| JP2021119185A (ja) | 2021-08-12 |
| WO2016145046A1 (en) | 2016-09-15 |
| JP2018507886A (ja) | 2018-03-22 |
| PL3267983T3 (pl) | 2024-05-13 |
| KR20170123329A (ko) | 2017-11-07 |
| JP7374149B2 (ja) | 2023-11-06 |
| JP6990110B2 (ja) | 2022-02-10 |
| CA2978883A1 (en) | 2016-09-15 |
| TW201642855A (zh) | 2016-12-16 |
| US20180036295A1 (en) | 2018-02-08 |
| EP4349408A2 (en) | 2024-04-10 |
| PT3267983T (pt) | 2024-03-12 |
| HUE065628T2 (hu) | 2024-06-28 |
| AU2016229826A1 (en) | 2017-10-26 |
| ES2973101T3 (es) | 2024-06-18 |
| US20200197374A1 (en) | 2020-06-25 |
| EA201791993A1 (ru) | 2017-12-29 |
| CN107872976A (zh) | 2018-04-03 |
| EP3267983A1 (en) | 2018-01-17 |
| HK1244217A1 (zh) | 2018-08-03 |
| EP4349408A3 (en) | 2024-06-19 |
| EP3267983B1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011598A (es) | Metodos para tratar proteinopatias. | |
| MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
| PT3873604T (pt) | Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| PH12016502095B1 (en) | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| SI3805233T1 (sl) | (r)in (s) enantiomera n-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo(4,5-b)piridin-6-il) -2-(2-metilpiridin-4-il)oksazol-karboksamid kot inhibitorji irak4 za zdravljenje raka | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| WO2014160871A3 (en) | Methods and agents for treating alzheimer's disease | |
| UA118209C2 (uk) | Гетероариламіди як інгібітори агрегації білків | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| BR112015001096A2 (pt) | derivados de di e tri-heteroaril como inibidores de agregação de proteína | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| SG10202009001TA (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2016008968A (es) | Compuestos organicos. | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| EP3634979A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS | |
| GB201911821D0 (en) | Compounds for use in the treatment of liver disease | |
| AU2018904309A0 (en) | Treatment of alzheimer's disease with augmenter of liver regeneration | |
| WO2019106572A3 (en) | Composition for treating and preventing diabetes mellitus type ii and alzheimer's disease |